Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Agenus Inc.
  6. News
  7. Summary
    AGEN   US00847G7051

AGENUS INC.

(AGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agenus : Says FDA Accepts Investigational New Drug Application for Cancer Drug Candidate; Closes License Deal With Bristol Myers Squibb

07/06/2021 | 11:11am EDT


ę MT Newswires 2021
All news about AGENUS INC.
09/17AGENUS : ESMO 2021 - Agenus Presents Updates on Balstilimab Plus Zalifrelimab Combination
PU
09/17ABCELLERA BIOLOGICS : Health Care Stocks Down to End Week
MT
09/17Health Care Stocks Mixed Premarket Friday
MT
09/17AGENUS : Says Cervical Cancer Combination Therapy Shows 'High' Response Rates in Phase 2 T..
MT
09/16Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in..
GL
09/14INSIDER SELL : Agenus
MT
09/10AGENUS : New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Co..
AQ
09/10Agenus Inc. Announces New Subsidiary, SaponiQx
CI
09/09AGENUS : to Participate in September Investor Conferences
AQ
09/07AGENUS : B. Riley Raises Agenus' PT to $12 from $11, Says Continued Regulatory Progress to..
MT
More news
Analyst Recommendations on AGENUS INC.
More recommendations
Financials (USD)
Sales 2021 263 M - -
Net income 2021 -95,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,4x
Yield 2021 -
Capitalization 1 375 M 1 375 M -
Capi. / Sales 2021 5,22x
Capi. / Sales 2022 13,9x
Nbr of Employees 359
Free-Float 87,2%
Chart AGENUS INC.
Duration : Period :
Agenus Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGENUS INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 5,90 $
Average target price 10,00 $
Spread / Average Target 69,5%
EPS Revisions
Managers and Directors
Garo H. Armen Chairman & Chief Executive Officer
Jennifer S. Buell President & Chief Operating Officer
Christine M. Klaskin Chief Financial & Accounting Officer, VP-Finance
Marc van Dijk Chief Technology Officer
Steven OĺDay Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGENUS INC.85.53%1 375
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353